Search

Displaying results 1981 - 1990 of 3601 in total
  1. Drug

    Regrelor

    go.drugbank.com/drugs/DB05553
    Investigational

    Categories: Purinergic P2 Receptor Antagonists
  2. Drug

    Binodenoson

    go.drugbank.com/drugs/DB04853
    Investigational

    Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A<sub>2A</sub> receptor.

    Categories: Purinergic P1 Receptor Agonists
  3. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A...

    Categories: Purinergic P1 Receptor Antagonists, Adenosine A2 Receptor Antagonists
  4. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

    Categories: Purinergic P1 Receptor Agonists
  5. Drug

    Aminophylline

    go.drugbank.com/drugs/DB01223
    ApprovedInvestigational

    Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

    Categories: Purinergic P1 Receptor Antagonists, Cytochrome P-450 Substrates
  6. Drug

    Ticagrelor

    go.drugbank.com/drugs/DB08816
    ApprovedInvestigational

    [A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.[A2903] Unlike [clopidogrel], ticagrelor is not a prodrug.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  7. Drug

    Theophylline

    go.drugbank.com/drugs/DB00277
    ApprovedInvestigational

    Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator.

    Categories: Purinergic P1 Receptor Antagonists, Cytochrome P-450 Substrates
  8. Drug

    Ticlopidine

    go.drugbank.com/drugs/DB00208
    Approved

    It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation.

    Categories: Purinergic P2 Receptor Antagonists, Purinergic P2Y Receptor Antagonists
  9. Drug

    Ethiodized oil

    go.drugbank.com/drugs/DB00965
    ApprovedInvestigational

    Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodo...

  10. Drug

    Arsenic trioxide

    go.drugbank.com/drugs/DB01169
    ApprovedInvestigational

    Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic ...

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors